+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032- Product Image
Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032- Product Image
New

Neoantigen Cancer Vaccine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5925178
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives and industry leaders are prioritizing the neoantigen cancer vaccine market as a pivotal opportunity in oncology’s shift toward precise, immune-driven treatments. Leveraging progress in personalized medicine, this sector enables new pathways for effective patient outcomes and streamlined immunotherapy deployment.

Market Snapshot: Neoantigen Cancer Vaccine Market Growth Trajectory

The Neoantigen Cancer Vaccine Market expanded from USD 17.51 billion in 2025 to USD 19.65 billion in 2026. Forecasts indicate a compounded annual growth rate (CAGR) of 13.15%, projecting the market to reach USD 41.58 billion by 2032. This momentum is attributed to surging demand for individualized immunotherapies and innovative vaccine platforms. Key drivers include advancements in sequencing technologies, computational biology, and manufacturing processes. Clinical trial adaptation, evolving regulatory standards, and increased investment in biotechnological research and development further support sustained market acceleration. As the field matures, organizations must remain agile to harness these growth vectors while addressing market access challenges and the shifting competitive landscape.

Scope & Segmentation

  • Neoantigen Types: Personalized neoantigens, which are custom-developed for individual patient tumor profiles, and shared neoantigens designed for use across broader populations.
  • Therapeutic Targets: Encompasses immune checkpoint modulators—including CTLA-4 and PD-1 inhibitors—as well as targeted strategies for both mutated and non-mutated neoantigens.
  • Vaccine Platforms: Includes a spectrum of modalities such as RNA-based, peptide-based, DNA-based, and cell-based vaccines, supporting distinct clinical applications and production efficiencies.
  • Administration Routes: Strategies tailored for intradermal, intravenous, oral, and subcutaneous administration, impacting dosing convenience and patient adherence.
  • End Users: Encompasses cancer treatment centers, hospitals, and research institutions—each providing unique entry points for adoption and implementation.
  • Regional Coverage: Americas, Europe Middle East & Africa, and Asia-Pacific regions, with each region presenting unique regulatory frameworks, market drivers, and supply chain complexities.
  • Technology Utilization: Leverages next-generation sequencing, advanced machine learning for epitope prediction, rapid synthesis methodologies, novel adjuvants, and modular manufacturing processes to optimize vaccine development and scalability.

Key Takeaways: Strategic Insights for Market Leadership

  • Neoantigen cancer vaccines offer superior immune precision, reducing the risk of adverse off-target effects compared to traditional tumor-antigen approaches.
  • Personalized and shared neoantigen models require tailored discovery and validation frameworks, implying different cost structures, operational workflows, and market adoption strategies.
  • Leading developers emphasize combination regimens, adaptive clinical trials, and outcome-focused program design to meet evolving payer and regulatory expectations.
  • Manufacturing is shifting towards decentralized and modular models, allowing improved flexibility and mitigation of logistical risks within increasingly complex supply chains.
  • Effective market access will depend on robust collaboration among biopharma companies, contract development and manufacturing organizations, payers, and clinical providers to ensure seamless patient access, data integration, and regulatory compliance.
  • Successful companies differentiate via specialized platforms, proprietary algorithms for neoantigen discovery, and strategic alliances that broaden manufacturing and commercial reach.

Tariff Impact: Strategic Responses in a Changing Global Supply Chain

Forthcoming United States tariff regulations scheduled for 2025 introduce additional challenges for the neoantigen vaccine sector. Increased duties on imported reagents, plasmids, and essential manufacturing inputs are anticipated to elevate operating costs and influence supplier selection. In response, organizations are exploring options to reshore or nearshore production activities, renegotiate supplier agreements, and diversify procurement strategies. Investments in localized manufacturing capacities are viewed positively, but often require additional capital allocation and stringent compliance measures. Changes in licensing, partnership structuring, and budgeting will be necessary as unit economics evolve. Companies may selectively leverage government incentives designed to support domestic manufacturing and product access, enabling more resilient supply chain strategies within this shifting commercial environment.

Methodology & Data Sources

This report synthesizes insights from direct interviews with clinical and manufacturing stakeholders, comprehensive reviews of leading clinical and regulatory literature, company disclosures, and in-depth supply chain analyses. Scenario-based sensitivity assessments and regulatory document scrutiny ensure that market intelligence remains actionable and validated.

Neoantigen Cancer Vaccine Market: Why This Report Matters

  • Equips decision-makers with actionable guidance on aligning research, manufacturing, and partnership strategies in a dynamic regulatory landscape.
  • Highlights effective approaches for mitigating supply chain risks and adapting to evolving global trade and tariff developments.
  • Offers a strategic framework for commercial planning, drawing on detailed segmentation and company-level competitive insights.

Conclusion

Neoantigen cancer vaccines are advancing the potential for personalized treatments in oncology. Strategic technology integration and proactive operational planning are vital for long-term market success. Industry leaders who adapt across these critical domains are positioned to influence the next generation of cancer care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neoantigen Cancer Vaccine Market, by Neoantigen Type
8.1. Personalized Neoantigens
8.1.1. Immune Escape Mutations
8.1.2. Somatic Mutations
8.2. Shared Neoantigens
8.2.1. Affinity Peptides
8.2.2. Common Tumor Mutations
9. Neoantigen Cancer Vaccine Market, by Therapeutic Target
9.1. Immune Checkpoint Blockade
9.1.1. CTLA-4 Inhibitors
9.1.2. PD-1 Inhibitors
9.2. Tumor Neoantigens
9.2.1. Mutated Neoantigens
9.2.2. Non-Mutated Neoantigens
10. Neoantigen Cancer Vaccine Market, by Vaccine Platform
10.1. Cell-Based Vaccines
10.1.1. Dendritic Cell Vaccines
10.1.2. T-Cell Vaccines
10.2. DNA-Based Vaccines
10.2.1. Circular DNA Platforms
10.2.2. Plasmid DNA Vaccines
10.3. Peptide-Based Vaccines
10.3.1. Long Peptides
10.3.2. Synthetic Peptides
10.4. RNA-Based Vaccines
10.4.1. mRNA Vaccines
10.4.2. Next-Gen RNA Platforms
11. Neoantigen Cancer Vaccine Market, by Administration Route
11.1. Intradermal
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Neoantigen Cancer Vaccine Market, by End User
12.1. Cancer Treatment Centers
12.2. Hospitals
12.3. Research Institutes
13. Neoantigen Cancer Vaccine Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Neoantigen Cancer Vaccine Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Neoantigen Cancer Vaccine Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Neoantigen Cancer Vaccine Market
17. China Neoantigen Cancer Vaccine Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Agenus Inc.
18.6. AstraZeneca PLC
18.7. Avidea Technologies
18.8. Ayala Pharmaceuticals, Inc.
18.9. BioLineRx Ltd.
18.10. BioNTech SE
18.11. BioVaxys Technology Corp.
18.12. Brightpath Biotherapeutics Co., Ltd.
18.13. CureVac N.V.
18.14. Elicio Therapeutics Inc
18.15. F. Hoffmann-La Roche Ltd.
18.16. Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
18.17. Genocea Biosciences Inc
18.18. GenScript Biotech Corporation
18.19. Gilead Sciences, Inc.
18.20. Gritstone bio, Inc.
18.21. Immunomic Therapeutics, Inc.
18.22. ISA Pharmaceuticals B.V.
18.23. Medigene AG
18.24. Merck & Co., Inc.
18.25. Moderna, Inc.
18.26. Neophore Limited
18.27. Nouscom AG
18.28. Nykode Therapeutics ASA
18.29. OSE Immunotherapeutics
18.30. Takis S.r.l.
List of Figures
FIGURE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE ESCAPE MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SOMATIC MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY AFFINITY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COMMON TUMOR MUTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MUTATED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NON-MUTATED NEOANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY T-CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CIRCULAR DNA PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PLASMID DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LONG PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEXT-GEN RNA PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 169. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 170. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 173. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 174. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 175. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 176. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 177. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 178. EUROPE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 195. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 196. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 197. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 198. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 199. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 200. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 201. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 202. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 203. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 204. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 205. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 206. AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 224. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 225. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 226. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 227. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 228. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 229. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 230. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 231. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 232. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 233. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 234. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 235. ASEAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 238. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 239. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 240. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 241. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 242. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 243. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 244. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 245. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 246. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 247. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 248. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 249. GCC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 266. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 267. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 268. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 269. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 270. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 271. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 272. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 273. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 274. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 275. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 276. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 277. BRICS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 279. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 280. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 281. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 282. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 283. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 284. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 285. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 286. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 287. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 288. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PEPTIDE-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 289. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 290. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 291. G7 NEOANTIGEN CANCER VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 293. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2032 (USD MILLION)
TABLE 294. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 295. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SHARED NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 296. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY THERAPEUTIC TARGET, 2018-2032 (USD MILLION)
TABLE 297. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, 2018-2032 (USD MILLION)
TABLE 298. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR NEOANTIGENS, 2018-2032 (USD MILLION)
TABLE 299. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
TABLE 300. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 301. NATO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DNA-BASED VACCINES, 2018-2032 (USD MILLION)
TABLE 302. NATO NEOANTIGEN CANCER

Companies Mentioned

The key companies profiled in this Neoantigen Cancer Vaccine market report include:
  • Agenus Inc.
  • AstraZeneca PLC
  • Avidea Technologies
  • Ayala Pharmaceuticals, Inc.
  • BioLineRx Ltd.
  • BioNTech SE
  • BioVaxys Technology Corp.
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac N.V.
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Genocea Biosciences Inc
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • ISA Pharmaceuticals B.V.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neophore Limited
  • Nouscom AG
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis S.r.l.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.65 Billion
Forecasted Market Value ( USD ) by 2032 $ 41.58 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Neoantigen Cancer Vaccines Market - Global Strategic Business Report - Product Image

Neoantigen Cancer Vaccines Market - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Neoantigen-Based Personalized Cancer Therapeutic Vaccines - Pipeline Insight, 2025 - Product Image

Neoantigen-Based Personalized Cancer Therapeutic Vaccines - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030 - Product Image

Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030

  • Report
  • 220 Pages
  • Global
From
Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence - Product Image

Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence

  • Directory
  • Global
From

About the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine market is a subset of the larger Cancer Vaccine market. Neoantigen Cancer Vaccines are a type of personalized cancer immunotherapy that uses a patient’s own tumor-specific mutations to create a vaccine tailored to their individual cancer. These vaccines are designed to stimulate the patient’s immune system to recognize and attack cancer cells. Neoantigen Cancer Vaccines are still in the early stages of development, but have shown promise in clinical trials. The Neoantigen Cancer Vaccine market is expected to grow as more personalized cancer treatments become available. Companies in the market include Moderna, BioNTech, CureVac, and Inovio Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.